/EINPresswire.com/ -- MONTREAL, QC--(Marketwired - October 03, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make a proffered paper oral presentation during the Central Nervous Systems Tumours session at the ESMO 2016 Congress in Copenhagen, Denmark from October 7-11, 2016. Angiochem's presentation will take place on October 7th.

"ESMO is a premiere conference that brings together oncology professionals from around the globe to share updates on groundbreaking cancer research," said John Huss, Executive Chairman of Angiochem. "As such, we are honored to be chosen to present and look forward to sharing our insights at this important event."

Angiochem is focused on developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain metastases.

                                                                            
Date:          October 7                                                    
                                                                            
Time:          16:45-17:00                                                  
                                                                            
Presenter:     Dr. Shou-Ching Tang, MD, PhD                                 
                                                                            
Abstract #:    324O                                                         
                                                                            
Title:         ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB
               and shows activity in patients with recurrent CNS metastasis 
               from breast cancer, results from a phase II clinical study   

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.

For more information, please contact:
Crystal Quast
Bullseye Corporate
647-529-6364
Quast@BullseyeCorporate.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.